Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Net Cash Flow (2016 - 2025)

Adma Biologics (ADMA) has disclosed Net Cash Flow for 13 consecutive years, with $26.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 59.64% year-over-year to $26.2 million, compared with a TTM value of -$15.5 million through Dec 2025, down 129.96%, and an annual FY2025 reading of -$15.5 million, down 129.96% over the prior year.
  • Net Cash Flow was $26.2 million for Q4 2025 at Adma Biologics, up from -$28.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $51.6 million in Q4 2022 and bottomed at -$31.5 million in Q1 2025.
  • Average Net Cash Flow over 5 years is $1.6 million, with a median of -$3.8 million recorded in 2024.
  • The sharpest move saw Net Cash Flow surged 741.44% in 2024, then tumbled 1780.29% in 2025.
  • Year by year, Net Cash Flow stood at $16.7 million in 2021, then soared by 209.48% to $51.6 million in 2022, then crashed by 144.18% to -$22.8 million in 2023, then surged by 172.09% to $16.4 million in 2024, then surged by 59.64% to $26.2 million in 2025.
  • Business Quant data shows Net Cash Flow for ADMA at $26.2 million in Q4 2025, -$28.9 million in Q3 2025, and $18.7 million in Q2 2025.